Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1996-2-22
|
pubmed:abstractText |
The pharmacokinetic interaction between atovaquone, a 1,4-hydroxynaphthoquinone, and zidovudine was examined in an open, randomized, three-phase crossover study in 14 patients infected with human immunodeficiency virus. Atovaquone (750 mg every 12 hours) and zidovudine (200 mg every 8 hours) were given orally alone and in combination. Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05). In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05). The maximum concentration of zidovudine-glucuronide was significantly lowered by atovaquone (5.7 +/- 1.5 versus 4.57 +/- 0.97 micrograms/ml; p < 0.05). Zidovudine had no effect on the pharmacokinetic disposition of atovaquone. Atovaquone appears to increase the AUC of zidovudine by inhibiting the glucuronidation of zidovudine.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Atovaquone,
http://linkedlifedata.com/resource/pubmed/chemical/Glucuronates,
http://linkedlifedata.com/resource/pubmed/chemical/Naphthoquinones,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0009-9236
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
14-21
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8549029-Adult,
pubmed-meshheading:8549029-Analysis of Variance,
pubmed-meshheading:8549029-Antiviral Agents,
pubmed-meshheading:8549029-Atovaquone,
pubmed-meshheading:8549029-Cross-Over Studies,
pubmed-meshheading:8549029-Glucuronates,
pubmed-meshheading:8549029-HIV Infections,
pubmed-meshheading:8549029-Humans,
pubmed-meshheading:8549029-Male,
pubmed-meshheading:8549029-Middle Aged,
pubmed-meshheading:8549029-Naphthoquinones,
pubmed-meshheading:8549029-Zidovudine
|
pubmed:year |
1996
|
pubmed:articleTitle |
Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine.
|
pubmed:affiliation |
Department of Medicine, University of California, San Francisco, San Francisco General Hospital 94110, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|